{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:56:50Z","timestamp":1793383010961,"version":"4.5.0"},"reference-count":74,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Healthcare"],"abstract":"<jats:p>Background\/Objective: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have received widespread attention as effective obesity treatments. However, limited research has examined the perspectives of patients contemplating GLP-1RAs. This study explored perceptions, motivations, and barriers among individuals considering GLP-1RA therapy for obesity treatment, with the goal of informing patient-centered care and enhancing clinician engagement. Methods: Adults completed surveys and interviews between June and November 2025. In this pragmatic mixed-methods study, both survey and interview questions explored perceived benefits, barriers, and decision-making processes. Qualitative data, describing themes based on the Health Belief Model, were analyzed using Dedoose (version 9.0.107), and quantitative data were analyzed using SAS (version 9.4). Participant characteristics included marital status, income, educational attainment, employment status, insurance status, age, race\/ethnicity, and sex. Anticipated length on GLP-1RA medication and selected self-reported health conditions (depression, anxiety, hypertension, heart disease, back pain, joint pain), reported physical activity level, and perceived weight loss competency were also recorded. Results: Among the 31 non-diabetic participants who were considering GLP-1RA medication for weight loss, cost emerged as the most significant barrier. Life course events, particularly (peri)menopause among women over 44, were commonly cited as contributors to weight gain. Participants expressed uncertainty about eligibility, long-term safety, and treatment expectations. Communication gaps were evident, as few participants initiated discussions and clinician outreach was rare, reflecting limited awareness and discomfort around the topic. Conclusions: Findings highlight that individuals considering GLP-1RA therapy face multifaceted emotional, financial, and informational barriers. Proactive, empathetic clinician engagement, through validation of prior efforts, clear communication of risks and benefits, and correction of misconceptions, can support informed decision-making and align treatment with patient goals.<\/jats:p>","DOI":"10.3390\/healthcare14020186","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T10:25:23Z","timestamp":1768213523000},"page":"186","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Considering Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) for Weight Loss: Insights from a Pragmatic Mixed-Methods Study of Patient Beliefs and Barriers"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6856-5319","authenticated-orcid":false,"given":"Regina","family":"DePietro","sequence":"first","affiliation":[{"name":"Department of Family and Community Medicine, University of Missouri, Columbia, MO 65211, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6610-2071","authenticated-orcid":false,"given":"Isabella","family":"Bertarelli","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Missouri, Columbia, MO 65211, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7772-1123","authenticated-orcid":false,"given":"Chloe M.","family":"Zink","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, University of Missouri, Columbia, MO 65211, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6577-8484","authenticated-orcid":false,"given":"Shannon M.","family":"Canfield","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, University of Missouri, Columbia, MO 65211, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8304-313X","authenticated-orcid":false,"given":"Jamie","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, University of Missouri, Columbia, MO 65211, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-747X","authenticated-orcid":false,"given":"Jane A.","family":"McElroy","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, University of Missouri, Columbia, MO 65211, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1111\/dom.16405","article-title":"GLP-1 medication and weight loss: Barriers and motivators among 1659 participants managed in a virtual setting","volume":"27","author":"Naveed","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s13679-025-00611-5","article-title":"The Impact of Novel Medications for Obesity on Weight Stigma and Societal Attitudes: A Narrative Review","volume":"14","author":"Heitmann","year":"2025","journal-title":"Curr. Obes. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e2455222","DOI":"10.1001\/jamanetworkopen.2024.55222","article-title":"Factors Associated with Semaglutide Initiation Among Adults with Obesity","volume":"8","author":"Podolsky","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as Compared with Semaglutide for the Treatment of Obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_5","unstructured":"Bozick, R., Donofry, S.D., and Rancano, K.M. (2025, August 14). New Weight Loss Drugs GLP-1 Agonist Use and Side Effects in the United States. Available online: https:\/\/www.rand.org\/pubs\/research_reports\/RRA4153-1.html."},{"key":"ref_6","unstructured":"Montero, A., Sparks, G., Presiado, M., and Hamel, L. (2025, August 14). KFF Health Tracking Poll May 2024: The Public\u2019s Use and Views of GLP-1 Drugs. Available online: https:\/\/www.kff.org\/health-costs\/poll-finding\/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs\/."},{"key":"ref_7","unstructured":"Centers for Disease Control and Prevention (CDC) (2025, August 14). Adult Obesity Facts, Available online: https:\/\/www.cdc.gov\/obesity\/adult-obesity-facts\/index.html."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/oby.24290","article-title":"Perceptions of anti-obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE Study","volume":"33","author":"Kaplan","year":"2025","journal-title":"Obesity"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/02813432.2025.2477141","article-title":"Patients\u2019 experiences with GLP1-Ras\u2014A systematic review","volume":"43","author":"Ibsen","year":"2025","journal-title":"Scand. J. Prim. Health Care"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41591-023-02669-x","article-title":"Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity","volume":"30","author":"Waldrop","year":"2024","journal-title":"Nat. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e70251","DOI":"10.1111\/hex.70251","article-title":"What Are the Experiences, Views and Perceptions of Patients, Carers and Clinicians of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs)? A Scoping Review","volume":"28","author":"Febrey","year":"2025","journal-title":"Health Expect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e783","DOI":"10.1002\/osp4.783","article-title":"Patient perspectives on incretin-based weight loss medications and relationship with demographic factors","volume":"10","author":"McVay","year":"2024","journal-title":"Obes. Sci. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e70085","DOI":"10.1002\/osp4.70085","article-title":"A Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss","volume":"11","author":"Plenn","year":"2025","journal-title":"Obes. Sci. Pract."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e002519","DOI":"10.1136\/bmjph-2024-002519","article-title":"What are community perspectives and experiences around GLP-1 receptor agonist medications for weight loss? A cross-sectional survey study in the UK","volume":"3","author":"Auerbach","year":"2025","journal-title":"BMJ Public Health"},{"key":"ref_15","first-page":"e40425","article-title":"Awareness and Perception of Anti-obesity Medications Among Al-Ahsaa, Riyadh, and Hail in Saudi Arabia Populations","volume":"15","author":"Almughais","year":"2023","journal-title":"Cureus"},{"key":"ref_16","unstructured":"Tyson, A., and Kikuchi, E. (2025, December 19). How Americans View Weight-Loss Drugs and Their Potential Impact on Obesity in the U.S. Available online: https:\/\/www.pewresearch.org\/science\/2024\/02\/26\/how-americans-view-weight-loss-drugs-and-their-potential-impact-on-obesity-in-the-u-s\/."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/osp4.686","article-title":"Health care providers\u2019 attitudes and counseling behaviors related to obesity","volume":"9","author":"Smith","year":"2023","journal-title":"Obes. Sci. Pract."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"490","DOI":"10.2337\/cd22-0100","article-title":"Health Care Provider Prescribing Habits and Barriers to Use of New Type 2 Diabetes Medications: A Single-System Survey Study","volume":"41","author":"Yaseen","year":"2023","journal-title":"Clin. Diabetes"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1002\/osp4.756","article-title":"Healthcare professionals\u2019 perceptions and management of obesity & knowledge of glucagon, GLP-1, GIP receptor agonists, and dual agonists","volume":"10","author":"Garvey","year":"2024","journal-title":"Obes. Sci. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Holtrop, J.S., Tietbohl, C., Perreault, L., Connelly, L., Smith, P.C., and Williams, J. (2025). Primary care patient and practice member perspectives on weight loss medications: Challenges and opportunities. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1584799"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100237","DOI":"10.1016\/j.obpill.2025.100237","article-title":"Taking back control: The experience of adults using semaglutide and tirzepatide for obesity treatment\u2014A qualitative study","volume":"17","author":"Trocchio","year":"2026","journal-title":"Obes. Pillars"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2307\/3348967","article-title":"Why people use health services","volume":"44","author":"Rosenstock","year":"1966","journal-title":"Milbank Mem. Fund. Q."},{"key":"ref_23","unstructured":"Alyafei, A., and Easton-Carr, R. (2024). The Health Belief Model of Behavior Change, StatPearls Publishing."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/ACM.0b013e31823ab7d2","article-title":"ResearchMatch: A national registry to recruit volunteers for clinical research","volume":"87","author":"Harris","year":"2012","journal-title":"Acad. Med."},{"key":"ref_25","unstructured":"SAS Institute Inc. (2023). SAS\u00ae software, Version 9.4, SAS Institute Inc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"114523","DOI":"10.1016\/j.socscimed.2021.114523","article-title":"Sample sizes for saturation in qualitative research: A systematic review of empirical tests","volume":"292","author":"Hennink","year":"2022","journal-title":"Soc. Sci. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1177\/1049732305276687","article-title":"Three approaches to qualitative content analysis","volume":"15","author":"Hsieh","year":"2005","journal-title":"Qual. Health Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): A 32-item checklist for interviews and focus groups","volume":"19","author":"Tong","year":"2007","journal-title":"Int. J. Qual. Health Care"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1111\/jan.13031","article-title":"Systematic methodological review: Developing a framework for a qualitative semi-structured interview guide","volume":"72","author":"Kallio","year":"2016","journal-title":"J. Adv. Nurs."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1037\/1040-3590.6.4.284","article-title":"Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology","volume":"6","author":"Cicchetti","year":"1994","journal-title":"Psychol. Assess."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1037\/h0031619","article-title":"Measuring nominal scale agreement among many raters","volume":"76","author":"Fleiss","year":"1971","journal-title":"Psychol. Bull."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Walsh, T.P., Arnold, J.B., Evans, A.M., Yaxley, A., Damarell, R.A., and Shanahan, E.M. (2018). The association between body fat and musculoskeletal pain: A systematic review and meta-analysis. BMC Musculoskelet. Disord., 19.","DOI":"10.1186\/s12891-018-2137-0"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/archgenpsychiatry.2010.2","article-title":"Overweight, obesity, and depression: A systematic review and meta-analysis of longitudinal studies","volume":"67","author":"Luppino","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1038\/s41366-025-01855-w","article-title":"Systematic literature review on the awareness of obesity in adults and children living with obesity, the general public and healthcare professionals","volume":"49","author":"Schreurs","year":"2025","journal-title":"Int. J. Obes."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrendo.2017.122","article-title":"Current pharmacotherapy for obesity","volume":"14","author":"Srivastava","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s13679-023-00534-z","article-title":"The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities","volume":"12","author":"Wadden","year":"2023","journal-title":"Curr. Obes. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Saran, A., Raisinghani, R., Paliwal, S., and Sharma, S. (2025). GLP-1R agonists: Recent advances, current gaps, and future challenges. Mol. Divers.","DOI":"10.1007\/s11030-025-11195-6"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.2147\/DDDT.S506957","article-title":"A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1\/GIP Receptor Agonist","volume":"19","author":"Min","year":"2025","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e250083","DOI":"10.57264\/cer-2025-0083","article-title":"Affordable access to GLP-1 obesity medications: Strategies to guide market action and policy solutions in the US","volume":"14","author":"Pearson","year":"2025","journal-title":"J. Comp. Eff. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2337\/cd24-0115","article-title":"Navigating Cost and Access Barriers for Medications in the Treatment of Obesity: A Guide for Patients and Primary Care Clinicians","volume":"43","author":"Herges","year":"2025","journal-title":"Clin. Diabetes"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/oby.23556","article-title":"Addressing insurance-related barriers to novel antiobesity medications: Lessons to be learned from bariatric surgery","volume":"30","author":"Gasoyan","year":"2022","journal-title":"Obesity"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e70041","DOI":"10.1002\/osp4.70041","article-title":"Views Among the General Public on New Anti-Obesity Medications and on the Perception of Obesity as a Failure of Willpower","volume":"11","author":"Goldkorn","year":"2025","journal-title":"Obes. Sci. Pract."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s12529-025-10353-2","article-title":"Comparing the Impact of GLP-1 Agonists vs. Lifestyle Interventions and Weight Controllability Information on Stigma and Weight-Related Cognitions","volume":"32","author":"Post","year":"2025","journal-title":"Int. J. Behav. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s13679-023-00495-3","article-title":"Obesity Stigma: Causes, Consequences, and Potential Solutions","volume":"12","author":"Westbury","year":"2023","journal-title":"Curr. Obes. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.2147\/DMSO.S539822","article-title":"Long-Term Efficacy Trajectories of GLP-1 Receptor Agonists: A Systematic Review and Network Meta-Analysis","volume":"18","author":"Li","year":"2025","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e2457349","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults with Overweight or Obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Merhi, Z., Karekar, M., and Mouanness, M. (2025). GLP-1 receptor agonist for weight loss and fertility: Social media and online perception versus evidence-based medicine. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0326210"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6032","DOI":"10.1007\/s00464-025-11938-4","article-title":"Evaluation of social media videos on weight-loss surgery and GLP-1 agonists: A content quality and reliability analysis","volume":"39","author":"Lee","year":"2025","journal-title":"Surg. Endosc."},{"key":"ref_50","unstructured":"(2025, November 10). The Center for Self-Determination Theory. Perceived Competence Scales (PCS). Available online: https:\/\/selfdeterminationtheory.org\/perceived-competence-scales\/."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/109019818801500203","article-title":"Social learning theory and the Health Belief Model","volume":"15","author":"Rosenstock","year":"1988","journal-title":"Health Educ. Q."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1479-5868-9-22","article-title":"Motivation, self-determination, and long-term weight control","volume":"9","author":"Teixeira","year":"2012","journal-title":"Int. J. Behav. Nutr. Phys. Act."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1479-5868-4-14","article-title":"Predicting short-term weight loss using four leading health behavior change theories","volume":"4","author":"Palmeira","year":"2007","journal-title":"Int. J. Behav. Nutr. Phys. Act."},{"key":"ref_54","unstructured":"Bandura, A. (1997). Self-Efficacy: The Exercise of Control, Henry Holt & Co."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12966-017-0494-y","article-title":"Effective behaviour change techniques for physical activity and healthy eating in overweight and obese adults; systematic review and meta-regression analyses","volume":"14","author":"Samdal","year":"2017","journal-title":"Int. J. Behav. Nutr. Phys. Act."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/109019818601300108","article-title":"The role of self-efficacy in achieving health behavior change","volume":"13","author":"Strecher","year":"1986","journal-title":"Health Educ. Q."},{"key":"ref_57","unstructured":"World Health Organization (2025, December 19). WHO Issues Global Guideline on the Use of GLP-1 Medicines in Treating Obesity. Available online: https:\/\/www.who.int\/news\/item\/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e254258","DOI":"10.1001\/jamahealthforum.2025.4258","article-title":"Glucagon-Like Peptide-1 Receptor Agonist Order Fills and Out-of-Pocket Costs by Race, Ethnicity, and Indication","volume":"6","author":"Sarpatwari","year":"2025","journal-title":"JAMA Health Forum"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e250905","DOI":"10.1001\/jamahealthforum.2025.0905","article-title":"Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity","volume":"6","author":"Hwang","year":"2025","journal-title":"JAMA Health Forum"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"McCall, K.L., Mastro Dwyer, K.A., Casey, R.T., Samana, T.N., Sulicz, E.K., Tso, S.Y., Yalanzhi, E.R., and Piper, B.J. (2025). Safety analysis of compounded GLP-1 receptor agonists: A pharmacovigilance study using the FDA adverse event reporting system. Expert. Opin. Drug Saf., 1\u20138.","DOI":"10.1080\/14740338.2025.2499670"},{"key":"ref_61","unstructured":"Novo Nordisk (2025, August 14). Tips for Prior Authorization. Available online: https:\/\/www.novomedlink.com\/content\/dam\/novonordisk\/novomedlink\/new\/obesity\/product-information\/resources\/library\/documents\/wegovy-tips-for-prior-authorizations.pdf."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jamainternmed.2025.1794","article-title":"Integrating Diet and Physical Activity When Prescribing GLP-1s-Lifestyle Factors Remain Crucial","volume":"185","author":"Mehrtash","year":"2025","journal-title":"JAMA Intern. Med."},{"key":"ref_63","first-page":"102214","article-title":"The expanding benefits of GLP-1 medicines","volume":"6","author":"Drucker","year":"2025","journal-title":"Cell Rep."},{"key":"ref_64","first-page":"860","article-title":"Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes","volume":"30","author":"Gleason","year":"2024","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41574-020-0364-6","article-title":"Obesity and impaired metabolic health in patients with COVID-19","volume":"16","author":"Stefan","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Aburto, S., Cisterna, M., Acu\u00f1a, J., Ru\u00edz, C., Viscardi, S., M\u00e1rquez, J.L., Villano, I., Letelier, P., and Guzm\u00e1n, N. (2022). Obesity as a Risk Factor for Severe COVID-19 in Hospitalized Patients: Epidemiology and Potential Mechanisms. Healthcare, 10.","DOI":"10.3390\/healthcare10101838"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat. Med."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Teixeira, P.J., Carra\u00e7a, E.V., Marques, M.M., Rutter, H., Oppert, J.M., De Bourdeaudhuij, I., Lakerveld, J., and Brug, J. (2015). Successful behavior change in obesity interventions in adults: A systematic review of self-regulation mediators. BMC Med., 13.","DOI":"10.1186\/s12916-015-0323-6"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"222s","DOI":"10.1093\/ajcn\/82.1.222S","article-title":"Long-term weight loss maintenance","volume":"82","author":"Wing","year":"2005","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e079783","DOI":"10.1136\/bmjopen-2023-079783","article-title":"Utilisation of the health belief model to study the behavioural intentions relating to obesity management among university students: A cross-sectional study","volume":"14","author":"Albasheer","year":"2024","journal-title":"BMJ Open"},{"key":"ref_71","unstructured":"(2018). The U.S. Burden of Disease Collaborators. The State of US Health, 1990\u20132016: Burden of Diseases, Injuries, and Risk Factors Among US States. JAMA, 319, 1444\u20131472."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Carter, R., and Moodie, M. (2010). The Cost-Effectiveness of Obesity Prevention. Obesity Epidemiology: From Aetiology to Public Health, Oxford University Press.","DOI":"10.1093\/acprof:oso\/9780199571512.003.0015"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1249\/MSS.0b013e3181f3818f","article-title":"Exercise autonomous motivation predicts 3-yr weight loss in women","volume":"43","author":"Silva","year":"2011","journal-title":"Med. Sci. Sports Exerc."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.37765\/ajmc.2025.89778","article-title":"Trends in glucagon-like peptide 1 receptor agonist prescribing patterns","volume":"31","author":"Ukhanova","year":"2025","journal-title":"Am. J. Manag. Care"}],"container-title":["Healthcare"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9032\/14\/2\/186\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T11:22:44Z","timestamp":1768216964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9032\/14\/2\/186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":74,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["healthcare14020186"],"URL":"https:\/\/doi.org\/10.3390\/healthcare14020186","relation":{},"ISSN":["2227-9032"],"issn-type":[{"value":"2227-9032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]}}}